Beyond glucose levels in diabetic patients with coronary artery disease: Platelet activity and non-responsiveness to antiplatelet therapy

Eduard Shantsila; Gregory Y. H. Lip

doi:10.1160/TH08-06-0342

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(01): 07-08
DOI: 10.1160/TH08-06-0342

Editorial Focus

Schattauer GmbH

Beyond glucose levels in diabetic patients with coronary artery disease: Platelet activity and non-responsiveness to antiplatelet therapy

Eduard Shantsila

¹Haemostasis Thrombosis andVascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK

,

Gregory Y. H. Lip

¹Haemostasis Thrombosis andVascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Compl 2001; 15: 44-54.
2 Evangelista V, Totani L, Rotondo S. et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005; 93: 8-16.
3 Varo N, Vicent D, Libby P. et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003; 107: 2664-2669.
4 van Werkum JW, Topcu Y, Postma S. et al. Effects of diabetes mellitus on platelet reactivity after dual anti-platelet therapy with aspirin and clopidogrel. Thromb Haemost 2008; 99: 637-639.
5 Serebruany V, Pokov I, Kuliczkowski W. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
6 Trovati M, Anfossi G, Cavalot F. et al. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988; 37: 780-786.
7 Udvardy M, Pfliegler G, Rak K. Platelet insulin receptor determination in non-insulin dependent diabetes mellitus. Experientia 1985; 41: 422-423.
8 Davì G, Gresele P, Violi F. et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
9 Ferroni P, Basili S, Falco A. et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 02: 1282-1291.
10 Eibl W, Krugluger N, Streit G. et al. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004; 34: 205-209.
11 Vallés J, Santos MT, Aznar J. et al. Modulatory effect of erythrocytes on the platelet reactivity to collagen in IDDM patients. Diabetes 1997; 46: 1047-1053.
12 Martina V, Bruno GA, Trucco F. et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 1998; 79: 520-522.
13 Morel O, Jesel L, Hugel B. et al. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003; 01: 171-177.
14 Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404.
15 Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280: H1480-H1489.
16 Rosado JA, Saavedra FR, Redondo PC. et al. Reduced plasma membrane Ca2+-AT Pase function in platelets from patients with non-insulin-dependent diabetes mellitus. Haematologica 2004; 89: 1142-1144.
17 Davì G, Ciabattoni G, Consoli A. et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
18 Davì G, Catalano I, Averna M. et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774.
19 Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists′Collaboration. Br Med J. 1994 308. 81-106.
20 Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT StudyGroup. Lancet 1998; 351: 1755-1762.
21 Steering Committee of the Physicians′ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians′ Health Study. N Engl J Med 1989; 321: 129-135.
22 Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.Aspirin effects on mortality and morbidity in patients with diabetes mellitus. J Am Med Assoc 1992; 268: 1292-1300.
23 Bhatt DL, Marso SP, Hirsch AT. et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-628.
24 Yusuf S, Zhao F, Mehta SR. et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N EnglJ Med 2001; 345: 494-502.
25 Watala C, Golanski J, Pluta J. et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113: 101-113.
26 NeriSerneri GG, Coccheri S, Marubini E. et al. Pi-cotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DA V ID study. Eur Heart J 2004; 25: 1845-1852.